4.32 USD
▲+0.54+6.67%
盘后 3.80 -6.17%
2026-08-03
市值
$102.78M
市盈率
—
EPS
-2.19
股息率
—
52 周区间
2.14 – 11.88
成交量
133.65K
Beta
—
目标价
18.71
52W 低 2.1452W 高 11.88
价格走势
公司简介
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeut...